Navigation Links
TB-drugome provides new targets for anti-tuberculosis drug discovery
Date:11/8/2010

Researchers at the University of California, San Diego School of Medicine and the University of Leeds have linked hundreds of federally approved drugs to more than 1,000 proteins in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), opening new avenues to repurpose these drugs to treat TB.

The study was published Nov. 4 in PLoS Computational Biology.

"Tuberculosis is currently one of the most widely spread infectious diseases, with an estimated one-third of the world's population infected and between one and two million people dying each year from the disease," said Philip Bourne, PhD, professor of pharmacology at UCSD's Skaggs School of Pharmacy and Pharmaceutical Sciences. "The continuing emergence of M. tuberculosis strains resistant to all existing, affordable drug treatments requires the development of novel, effective and inexpensive drugs.

The newly developed TB-drugome may help that effort, Bourne said, by identifying new M. tuberculosis protein targets that can be perturbed by a variety of existing drugs prescribed for other purposes.

Sarah Kinnings at the University of Leeds and a team of scientists at UC San Diego, led by Bourne (who is also associate director of the RCSB Protein Data Bank) and research scientist Lei Xie, PhD, used a novel computational strategy to investigate whether any existing drugs were able to bind to any of the approximately 40 percent of proteins in the M. tuberculosis proteome with decipherable three-dimensional structures.

The researchers not only discovered that approximately one-third of the drugs examined may have the potential to be repurposed to treat tuberculosis, but also that many currently unexploited M. tuberculosis proteins could serve as novel anti-tubercular targets. This finding led the investigators to construct a complex network of drug-target interactions a TB-drugome available to all scientists.

While this new computational, high-throughput process of drug discovery is promising, Xie cautioned that "only experimentation can validate the most promising drug-target combinations, and there will be many failures along the way."

Kinnings added that any drugs subsequently confirmed to bind to M. tuberculosis proteins may need to be modified to increase their ability to penetrate the bacterial cell membrane, reduce their required dosage, and improve other pharmacological properties. The screening of a large collection of analogs to known drugs will be the next step towards anti-tuberculosis drug discovery.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related biology news :

1. Study provides treatment hope for long term effects of brain trauma
2. 100-million-year-old mistake provides snapshot of evolution
3. UF research provides new understanding of bizarre extinct mammal
4. Study provides data that can inform Atlantic sturgeon recovery efforts
5. Protein provides link between calcium signaling in excitable and non-excitable cells
6. Going green: New program provides vital support for plant scientists
7. Hair provides proof of the link between chronic stress and heart attack
8. LSUHSC pediatric weight expert provides obesity trinity answers
9. Special edition journal provides new perspectives and guidance for managing white pine blister rust
10. Huntingtons disease discovery provides new hope for treatment
11. De La Rue Provides Second-Generation ePassport for Malta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... LAVAL, QC , Jan. 24, 2017 /PRNewswire/ - ProMetic ... the "Corporation") announced today that its orally active lead ... Medicine ("PIM") designation by the UK Medicines and Healthcare ... Syndrome ("AS"). A PIM designation is ... promising candidate for the Early Access to Medicines Scheme ...
(Date:1/24/2017)... ... , ... Oklahoma City based Sigma Blood Systems has established a relationship with ... legacy product QC Manager 2.0. , Sigma Blood Systems CEO, Max Doleh, stated ... they have decided to implement PERFEQTA and QC Manager 2.0, with PERFEQTA launching across ...
(Date:1/24/2017)...   Instrument Business Outlook ( IBO ... ) the 2016 Company of the Year. ... tracking developments in the analytical and life science ... achieved outstanding technical, operational and financial results throughout ... IBO. "In 2016, Bio-Techne capitalized on opportunities in ...
(Date:1/23/2017)... ... January 23, 2017 , ... USARAD Holdings Inc., a ... last year adding 65 new US and international facilities to its client base. ... well as one of US largest imaging center chains. USARAD continued its global ...
Breaking Biology Technology: